MaaT Pharma Announces First Patient Dosed in Phase 3 'ARES' Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
Pivotal Phase 3 clinical trial investigates the efficacy of lead Microbiome Ecosystem Therapy MaaT013 as third-line treatment in patients with steroid-resistant gastrointestinal acute Graft-versus-Host
United States Mohamad Mohty Cellular Therapy Department Drug Administration Trophic Communications Senior Pr Corporate Communications
Source: finanznachrichten.de